18F-DCFPyL Positron Emission Tomography (PET)/Computed Tomography (CT) in Men With Prostate Cancer
| Status: | Recruiting |
|---|---|
| Conditions: | Prostate Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 3/31/2019 |
| Start Date: | February 12, 2019 |
| End Date: | December 2023 |
| Contact: | Lisa Olmos, RN |
| Email: | cancerclinicaltrials@cumc.columbia.edu |
| Phone: | 212-342-5162 |
PyL, also known as [18F]DCFPyL, is a second-generation fluorinated prostate-specific membrane
antigen (PSMA) targeted PET imaging agent. In preliminary studies it demonstrates a higher
detection of metastatic prostate lesions compared to standard imaging. Its ability to image
metastatic prostate cancer sites was comparable to 68Ga-PSMA with high tumor-to-background
ratios.Additionally, [18F] PyL demonstrated higher mean tumor-to-background ratios when using
kidney, spleen, or parotid as reference organs. However, the role of [18F] PyL in tumor
response to therapy has not been evaluated, specifically the potential to serve as a
predictive biomarker of response. Given the high cost of current therapeutic agents in mCRPC,
there is a need for an early response biomarker to stratify which patients will benefit from
therapy and which will not. This will also allow for earlier change in management of patients
who will not response to these therapies, potentially improving patient outcomes.
antigen (PSMA) targeted PET imaging agent. In preliminary studies it demonstrates a higher
detection of metastatic prostate lesions compared to standard imaging. Its ability to image
metastatic prostate cancer sites was comparable to 68Ga-PSMA with high tumor-to-background
ratios.Additionally, [18F] PyL demonstrated higher mean tumor-to-background ratios when using
kidney, spleen, or parotid as reference organs. However, the role of [18F] PyL in tumor
response to therapy has not been evaluated, specifically the potential to serve as a
predictive biomarker of response. Given the high cost of current therapeutic agents in mCRPC,
there is a need for an early response biomarker to stratify which patients will benefit from
therapy and which will not. This will also allow for earlier change in management of patients
who will not response to these therapies, potentially improving patient outcomes.
The investigators will conduct a prospective phase II/III study of 300 men diagnosed with
prostate cancer with a rising prostate-specific antigen (PSA). Upon enrollment, subjects will
undergo standard of care imaging (defined as a CT or MRI of the chest, abdomen, and pelvis,
and 99mTc bone scans) if not obtained within 45 days of enrollment. Subjects will have
standard of care laboratory evaluations and undergo 18F- DCFPyL PET/CT.
[18F]DCFPyL will be used for study imaging.
prostate cancer with a rising prostate-specific antigen (PSA). Upon enrollment, subjects will
undergo standard of care imaging (defined as a CT or MRI of the chest, abdomen, and pelvis,
and 99mTc bone scans) if not obtained within 45 days of enrollment. Subjects will have
standard of care laboratory evaluations and undergo 18F- DCFPyL PET/CT.
[18F]DCFPyL will be used for study imaging.
Inclusion Criteria:
1. Histologically confirmed diagnosis of prostate cancer
2. PSA ≥ 0.2ng/ml
3. Age ≥ 18 years of age
4. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 (karnofsky ≥ 60%)
5. Ability to understand and willingness to sign a written informed consent document
6. Wiling to comply with clinical trial instructions and requirements
7. Able to cover the cost of PyL PET/CT imaging
Exclusion Criteria:
1. History of another active malignancy within 3 years, other than basal cell and
squamous cell carcinoma of the skin
2. Presence of prostate brachytherapy implants
3. Administration of another radioisotope within five physical half-lives of trial
enrollment
4. Radiation or chemotherapy within 2 weeks prior to trial enrollment
5. Serum creatinine > 3 times the upper limit of normal
6. Serum total bilirubin > 3 times the upper limit of normal
7. Aspartate transaminase (AST) or alanine aminotransferase (ALT) >5 times the upper
limit of normal
8. Inadequate venous access
We found this trial at
1
site
630 W 168th St
New York, New York
New York, New York
212-305-2862
Principal Investigator: Emerson Lim, MD
Columbia University Medical Center Situated on a 20-acre campus in Northern Manhattan and accounting for...
Click here to add this to my saved trials
